

Steven Le Guill

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/2317821/steven-le-gouill-publications-by-year.pdf>

Version: 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

18
papers

586
citations

11
h-index

20
g-index

20
ext. papers

819
ext. citations

4.7
avg, IF

2.91
L-index

#	Paper	IF	Citations
18	No survival improvement in patients with high-risk multiple myeloma harbouring del(17p) and/or t(4;14) over the two past decades. <i>British Journal of Haematology</i> , 2021 , 194, 635-638	4.5	1
17	Ibrutinib, obinutuzumab, and venetoclax in relapsed and untreated patients with mantle cell lymphoma: a phase 1/2 trial. <i>Blood</i> , 2021 , 137, 877-887	2.2	21
16	Obinutuzumab vs rituximab for advanced DLBCL: a PET-guided and randomized phase 3 study by LYSA. <i>Blood</i> , 2021 , 137, 2307-2320	2.2	16
15	Lenalidomide/rituximab induces high molecular response in untreated follicular lymphoma: LYSA ancillary RELEVANCE study. <i>Blood Advances</i> , 2020 , 4, 3217-3223	7.8	8
14	Predictive factors of early progression after CAR T-cell therapy in relapsed/refractory diffuse large B-cell lymphoma. <i>Blood Advances</i> , 2020 , 4, 5607-5615	7.8	58
13	RAS mutation leading to acquired resistance to dabrafenib and trametinib therapy in a multiple myeloma patient harboring BRAF mutation. <i>EJHaem</i> , 2020 , 1, 318-322	0.9	1
12	The MYRACLE protocol study: a multicentric observational prospective cohort study of patients with multiple myeloma. <i>BMC Cancer</i> , 2019 , 19, 855	4.8	1
11	Treatment for patients with relapsed/refractory mantle cell lymphoma: European-based recommendations. <i>Leukemia and Lymphoma</i> , 2018 , 59, 1814-1828	1.9	15
10	BH3-mimetic toolkit guides the respective use of BCL2 and MCL1 BH3-mimetics in myeloma treatment. <i>Blood</i> , 2018 , 132, 2656-2669	2.2	37
9	Deep and sustained response after venetoclax therapy in a patient with very advanced refractory myeloma with translocation t(11;14). <i>Haematologica</i> , 2017 , 102, e112-e114	6.6	32
8	Consolidation anti-CD22 fractionated radioimmunotherapy with Y-epratuzumab tetraxetan following R-CHOP in elderly patients with diffuse large B-cell lymphoma: a prospective, single group, phase 2 trial. <i>Lancet Haematology</i> , 2017 , 4, e35-e45	14.6	23
7	BH3 profiling as a tool to identify acquired resistance to venetoclax in multiple myeloma. <i>British Journal of Haematology</i> , 2017 , 179, 684-688	4.5	17
6	Complete donor T cell chimerism predicts lower relapse incidence after standard double umbilical cord blood reduced-intensity conditioning regimen allogeneic transplantation in adults. <i>Biology of Blood and Marrow Transplantation</i> , 2015 , 21, 180-4	4.7	10
5	Cell death via DR5, but not DR4, is regulated by p53 in myeloma cells. <i>Cancer Research</i> , 2012 , 72, 4562-730.1	10.1	50
4	Graft-versus-lymphoma effect for aggressive T-cell lymphomas in adults: a study by the Société Française de Greffe de Moelle et de Thérapie Cellulaire. <i>Journal of Clinical Oncology</i> , 2008 , 26, 2264-71	2.2	238
3	Efficacy of Imatinib-Based Therapy in a Patient with Resistant NUP214-ABL1 T-Cell Acute Lymphoblastic Leukemia.. <i>Blood</i> , 2007 , 110, 4329-4329	2.2	
2	High Grade Non-Hodgkin's Lymphoma with Tandem t(14;18) and c-MYC Rearrangement Is a Pathological Lymphoma Entity with Aggressive Clinical Presentation and Very Poor Prognosis.. <i>Blood</i> , 2006 , 108, 2045-2045	2.2	

- 1 Melphalan-induced apoptosis in multiple myeloma cells is associated with a cleavage of Mcl-1 and Bim and a decrease in the Mcl-1/Bim complex. *Oncogene*, **2005**, 24, 8076-9 9.2 55